摘要
目的:评价阿立哌唑对首发精神分裂症患者的临床疗效和生活质量的影响。方法:将70例首发精神分裂症患者随机分为阿立哌唑组(35例)和氟哌啶醇组(35例),疗程12周。采用阳性和阴性症状量表(PANSS)评定疗效,生活质量综合评定问卷(GQOLI-74)评定生活质量,不良反应量表(TESS)和实验室检查评定药物不良反应。结果:阿立哌唑组和氟哌啶醇组分别完成了33例和32例。治疗后各评分时点阿立哌唑组PANSS总分及因子分与基线相比均显著下降(P<0.05或P<0.01);氟哌啶醇组PANSS阴性症状因子分从4周末开始显著下降(t值分别为2.063、3.585和4.172,P<0.05或P<0.01);其余因子各时点与治疗前相比均存在显著性差异(P<0.05或P<0.01)。治疗8周末和12周末阿立哌唑组PANSS阴性症状因子分明显低于氟哌啶醇组(t值分别为-2.424和-2.589,P均<0.05)。12周末,阿立哌唑组的有效率为87.88%,氟哌啶醇组为87.50%,两组间比较无显著性差异(x2值=0.110,P>0.05)。12周末,阿立哌唑组GQOLI总分、躯体健康、心理健康、社会功能维度均显著改善(P均<0.01),而氟哌啶醇组生活质量因子评分治疗前后差异无显著性。阿立哌唑组不良反应少。结论:阿立哌唑与氟哌啶醇对精神分裂症的疗效相当,但阿立哌唑对精神分裂症患者阴性症状和生活质量改善明显,不良反应少。
Objective： To evaluate clinical effects of aripiprazole and its effects on quality of life for first - episode schizophren- ic patients. Methods ：70 first - episode schizophrenic patients were randomly divided into aripiprazole group （n = 35） and haloperidol group （n = 35） and treated for 12 weeks. The efficacy was measured by positive and negative syndrome scale（ PANSS）, the quality of life was evaluated by general quality of life inventory （GQOL1-74）, and the side effects were assessed by treatment emergent symp- toms scale （TESS） and related lab tests. Results： Aripiprazole and haloperidol were used for treating 33 and 32 cases, respectively. After the treatment, the total score and factor scores of PANSS in aripiprazole group significantly decreased compared with the baselines at each scoring time point （P 〈 0. 05 or P 〈 0. 01 ）. Compared with those before the treatment, the factor scores of the negative symp- toms in haloperidol group started to significantly decrease （ t = 2. 063, 3. 585 and 4. 172, P 〈 0.05 or 0.01 ） from 4 weeks after the treatment, and there were significant differences for other factors at each time point before and after the treatment （ P 〈 0.05 or P 〈 0. 01 ）. The negative symptom factor scores of aripiprazole group were significantly lower than those of haloperidol group 8 and 12 weeks after the treatment （t = - 2.424 and - 2. 589, respectively, both P 〈 0.05 ）. 12 weeks after the treatment, the clinical effective rate was 87.88% for aripiprazole group and 87.50% for haloperidol group, and the difference was not statistically significant （x2 = 0.110, P 〉 0.05 ）. The total score of GQOLI, physical health, mental health and social functions in aripiprazole group were improved signifi- cantly （P 〈 0. 01 ） 12 weeks after the treatment; however, there were no significant differences in the factor scores of GQOLI for halo- peridol group before and after treatment. The side effects in aripiprazole group were lower than those in haloperidol group. Conclusions： Compared with with haloperidol, aripiprazole has a similar efficacy; further, aripiprazole can significantly reduce the negative symptoms and improve the quality of life for schizophrenic patients, and has fewer side effects.
出处
《中国民康医学》
2013年第11期35-38,共4页
Medical Journal of Chinese People’s Health
关键词
阿立哌唑
氟哌啶醇
首发精神分裂症
生活质量
Aripiprazole
Haloperidol
First - episode schizophrenia
Quality of life
